Human health and biomarker development
Research within this group is aimed at the development of diagnostic and therapeutic agents that directly benefit the health of community members, in particular discoveries that improve treatment of metabolic disorders, cancer and cardiovascular, infectious and autoimmune diseases. Group members already have an integrated research development pipeline in specialised areas such as: biomarker and genomic discoveries; vaccine and diagnostic development; antibody generation; preclinical evaluation and disease correlation; and therapeutic and clinical testing.
Group members
| Name | Area of research |
|---|---|
| A/Prof Stuart Berzins | Cancer; Autoimmune diseases |
| Dr Phillip Brook-Carter | Genomics; Parasitic infection |
| Prof Fadi Charchar | Cardiovascular and renal diseases |
| Dr Greg Davis | DNA damage repair and developmental RNA biology |
| Dr Andrew Greenhill | Infectious disease in low-income countries |
| A/Prof Mark Myers | Metabolic diseases; Cancer |
| Dr Scott Nankervis | Metabolic diseases |
| Dr Morgan Wallace | Cancer |
| Dr Yutang Wang | Cardiovascular and neuronal diseases |